Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 441, 451-456 (25 May 2006) | doi:10.1038/nature04873; Published online 24 May 2006
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellow in Immunology
- The Scripps Research Institute
- N Torrey Pines Rd, San Diego, CA, USA
Head of Analytical R&D
- Syngene International Limited
- Bangalore 560 099 India
Review Article Validating cancer drug targets
John D. Benson1, Ying-Nan P. Chen1, Susan A. Cornell-Kennon1, Marion Dorsch1, Sunkyu Kim1, Magdalena Leszczyniecka1, William R. Sellers1 & Christoph Lengauer1
Abstract
A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.
To read this story in full you will need to login or make a payment (see right).
